ASTRAZENECA PLC (AZN) — Equity Research Note

Executive summary

AstraZeneca is a global science-led biopharmaceutical company with a diversified franchise across Oncology (46% of revenue), BioPharmaceuticals (CVRM + R&I + Infectious Disease, ~36%) and Rare Disease (16%), led by blockbuster medicines such as Tagrisso, Imfinzi, Calquence, Enhertu, Lynparza, Farxiga and Ultomiris. Across 2022–H1 2026 the group delivered consistent high-single-digit CER top-line growth and low-teens Core EPS growth, with Total Revenue rising from $44.4bn (FY22) to $58.7bn (FY25) and the company reaffirming its $80bn 2030 ambition at the H1 2026 report 2026-07-27 half-year. The valuation question today is whether the shares — down ~24% from the February 2026 peak of 15,542p to 11,870p — adequately discount two overhangs: Farxiga US loss-of-exclusivity, and recent high-profile trial setbacks (CARDIO-TTRansform, EMERALD-2) against a still-rich pipeline of 20+ Phase III readouts in the next 18 months.

Fair value estimate

• Fair value range: 12,000p – 15,000p per share (implied market cap £186bn – £233bn).
• Methodology: forward P/E on Core EPS. FY 2025 Core EPS was $9.16; guidance for FY 2026 is low double-digit growth, implying ~$10.20. At a 15–18× forward multiple (in line with large-cap pharma peers given a decade of double-digit earnings growth ambition), that is $153–$184 per share. Converting at ~1.27 USD/GBP and 1.55bn shares outstanding gives a per-share range of ~12,050p – 14,500p, with a mid-case near 13,275p. A supportive EV/EBITDA cross-check (~12× FY26 EBITDA of ~$21bn + net debt $27bn) lands in the same corridor.
• Vs. current market cap of £184,092m: current price 11,870p sits just below the low end. Upside to mid-case ~12%, upside to top of range ~26%, downside to low case roughly flat.
• View: fair to modestly undervalued.

Sector context

• Confirmed sector: Health Care / Pharmaceuticals (ICB Super-Sector Health Care).
• Quality profile is above typical sector peers: industry-leading R&D productivity (30+ approvals in 7 months per H1 2026 report), broadest late-stage oncology pipeline, Core Operating Margin 34%, Core Gross Margin ~83% 2026-07-27 half-year. Growth is at the top end of big pharma, with ambition to deliver $80bn Total Revenue by 2030 vs. ~$59bn today.
• Listed peers: Novartis, Roche, Merck & Co., Pfizer, Eli Lilly, GSK, Novo Nordisk. AZN sits with Lilly and Novo as the premium growth names in the group.

Investment thesis (three bullets)

1. Multi-year revenue growth secured by a differentiated late-stage pipeline: 30 regulatory approvals in major regions in the first seven months of 2026 alone, with 20+ high-value Phase III readouts due over the next 18 months and management reiterating the $80bn 2030 revenue ambition "which assumes successes and setbacks" 2026-07-27 half-year. Oncology grew 15% CER in H1 2026 driven by Imfinzi (+29%), Calquence (+16%), Enhertu (+32%), Truqap (+41%) and Datroway (+6× from launch).
2. Operating leverage is working as planned: Core Operating Profit grew 11% in H1 2026 on 6% CER revenue growth; Core Operating Margin of 34% (up 1pp) demonstrates that incremental revenue on an existing marketed base is still dropping through at an attractive rate, even as the company adds R&D investment (now 23% of revenue) and absorbs US Farxiga LoE and China VBP headwinds 2026-07-27 half-year.
3. Valuation does not require a bull case: at 16.5× trailing Core EPS and ~15× FY26E, AZN is below its 2024-25 trading band despite guidance reaffirmed and no deterioration in competitive position. Investor sentiment appears to have overshot on three recent Phase III misses (CARDIO-TTRansform, EMERALD-2 adj HCC, TMA-313) that were already explicitly contemplated in management's "successes and setbacks" framework 2026-07-27 half-year.

Key risks (three bullets)

1. Farxiga US patent cliff is now cutting: Farxiga revenue fell 11% CER in H1 2026 ($4,042m H1 revenue, with US –17%) after multiple generics launched Q2 2026, and will continue to decline in 2027 2026-07-27 half-year. Farxiga was 13% of 2025 revenue — the Oncology + Rare Disease ramp needs to run faster than this amortising decline.
2. Pipeline binary-outcome risk: three Phase III failures already disclosed in 2026 (CARDIO-TTRansform/Wainua in ATTR-CM, EMERALD-2/Imfinzi adj HCC, ALXN1210-TMA-313/Ultomiris in HSCT-TMA), and the discontinuation of PACIFIC-8 and ceralasertib/LATIFY in late 2025, show the base rate of pipeline misses is non-trivial for a company that has set a $80bn target 2026-07-27 half-year; 2026-02-10 final results.
3. China exposure and governance overhang: Q2 2026 China revenue down 13% CER; the November 2025 indictments of a former EVP and employees for personal-information infringement and illegal trade, and ongoing medical-insurance fraud charges, remain unresolved although AstraZeneca itself was not charged with insurance fraud 2026-07-27 half-year. China was 11% of H1 2026 revenue; VBP, generic competition and geopolitics are structural pressures.

Operating leverage

Pharma delivers moderate but real operating leverage once a franchise is approved and launched. H1 2026 numbers help quantify it for AstraZeneca: Core Gross Margin 83%, Core SG&A ratio 26%, Core R&D ratio 23%, giving Core Operating Margin ~34% 2026-07-27 half-year. SG&A and R&D are substantially fixed in the near term — AZ runs ~100 Phase III trials and the sales infrastructure to support 16 blockbusters globally regardless of month-to-month volume. On the current base, an incremental $1bn of revenue on a mature marketed product (gross margin ~85%, modest incremental SG&A) likely drops ~70–80 cents through to operating profit; i.e. a 10% revenue beat vs. plan could translate into ~15–20% operating profit upside. That is good but not spectacular — well below pure-software leverage. The gating constraint on the long tail is R&D intensity, which the company is actively reinvesting rather than letting flow through: FY 2026 R&D is expected to continue growing with mid-single-digit SG&A increases 2026-02-10 final results. This caps near-term upside surprise but is the right strategy for sustaining growth beyond 2030. Observable inflection points: full ramp of Datroway, camizestrant, Baxfendy, Truqap, Breztri and gefurulimab; and the oral GLP-1/GIPR elecoglipron Phase III, which could re-rate the stock given the obesity opportunity.

Value-trap signals

• US Farxiga erosion: generic entry Q2 2026 is now cutting into revenue, requiring the pipeline to run faster than LoE for several years.
• China revenue pressure: ongoing VBP (volume-based procurement) programmes, generic competition, and NRDL pricing concessions mean this historically high-growth region is barely growing at CER. 2026-07-27 half-year
• Rising net debt: from $23.4bn end-FY25 to $26.9bn at H1 2026 end, driven by Dizal, CSPC, Fusion, Icosavax, Amolyt and smaller deals; still manageable at ~1.3× EBITDA but worth monitoring.
• Not identified as value traps: no dividend cut (dividend raised to $3.30 for FY26); no going concern; no accounting restatements; no material customer concentration; no terminal-decline exposure.

Earnings vs. expectations

Across the covered period, AstraZeneca has displayed a beat-and-raise pattern. FY 2024 Total Revenue (+21% CER) came in above initial guidance of a "low double-digit to low teens percentage"; FY 2025 was guided to "mid teens" and delivered 8% at CER after a bigger-than-expected Vaxzevria/COVID-19 headwind, but Core EPS of $9.16 was within the "low double-digit" guided range. For H1 2026, Core EPS was +11% CER against a FY guide of "low double-digit" growth, i.e. tracking in line to slightly ahead. Overall: more beats than misses, with management typically guiding conservatively and increasing guidance mid-year (as in H1 2024 when both revenue and EPS guidance were raised to mid-teens). Rating: consistent in-line to beat.

Conviction

4 — high. The business is well-disclosed, the Core EPS bridge is clearly reconciled from Reported, management track record on guidance is strong, and multiple cross-check methodologies (forward P/E, EV/EBITDA, sum-of-parts on franchise basis) land in a similar fair-value range. Anchors: predictable multi-brand revenue base, clean guidance history, broad analyst coverage. Limits: single-trial binary outcomes could meaningfully reshape the $80bn 2030 trajectory, and the FX/China sensitivity creates ongoing noise.